Resources
Clear thinking on pharma portfolio and project governance.
Short, practical explainers for the decisions pharma leaders, PMOs, and finance teams actually make.
Insights
From Molecule Strategy to Execution
Closing the Gap in Pharma Portfolio Management
ReadInsights
When the Portfolio Is Full, What Moves?
A Full Portfolio does not eliminate choice. It makes choice more consequential. The strongest opportunities shouldn't wait for capacity. They should change what already had priority. A practical framework for evaluating new molecule…
ReadRisk
PTRS, explained for portfolio decisions
Probability of technical and regulatory success is the number every phase-gate turns on. Here is how it fits alongside business, IP, API/supply, and KSM risk.
ReadGovernance
What is pharma portfolio governance?
Why R&D-heavy pharma organisations are moving from status packs and email ownership to a governed operating model - and what that actually means day to day.
ReadFinance
eNPV vs NPV for pharma portfolios
Two molecules can share the same NPV and be worth very different amounts to your pipeline. Risk-adjusted value is why - and how leaders should use it.
ReadInsights
Welcome to the PortiVix resource hub
A quick look at how our editorial team publishes practical guides on pharma portfolio and project governance.
Read
See your portfolio operating model in PortiVix.
We do not start with a generic demo. We map your portfolio, molecule, project, approval, reporting, and governance workflows first, then show how PortiVix would work for your organisation.
Or write to marketing@virtunx.com